Loading
H3-3B (Histone H3.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Melanoma and Diffuse midline glioma, H3 K27-altered.
Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis. Deposited at sites of nucleosomal displacement throughout transcribed genes, suggesting that it represents an epigenetic imprint of transcriptionally active chromatin.
CIViC holds 2 clinical evidence items and 1 assertion across 3 variants. Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.28, affected pathway 0.76, genetic association 0.00, somatic mutation 0.95).
In plain words · H3-3B (Histone H3.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Melanoma and Diffuse midline glioma, H3 K27-altered.
H3-3B (Histone H3.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Melanoma and Diffuse midline glioma, H3 K27-altered.
Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis.
No product in this corpus aims at H3-3B yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA H3-3B: RNA tissue enhanced (bone marrow 3,984 nTPM); blood lineage lineage enriched (granulocytes 21,236 nTPM); high antibody staining in 45 normal tissues; highest cancer staining glioma (12 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Brain and spinal cord tumours (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (glioma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas H3-3B tissue; Open Targets ENSG00000132475 associations
First described 1981. Earliest sequence paper UniProt cites for the protein: Ohe et al, J. Biochem, 1981, "Human spleen histone H3. Isolation and amino acid sequence". Source.
Sources: HGNC HGNC:4765 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P84243 (protein name, function text, keywords and locations (REST API)); CIViC gene H3-3B (2 evidence items, 1 assertions, 3 variants; diseases: Chondroblastoma, Diffuse Midline Glioma, H3 K27-altered (GraphQL API, CC0)); Open Targets ENSG00000132475 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: melanoma 0.63, skin cancer 0.55 (GraphQL API, CC0))
Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis. Deposited at sites of nucleosomal displacement throughout transcribed genes, suggesting that it represents an epigenetic imprint of transcriptionally active chromatin. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Location: Nucleus; Chromosome (UniProt). Locus 17q25.1 (HGNC).
RNA: tissue enhanced (bone marrow 3,984 nTPM), detected in all normal tissues. Blood: lineage enriched (granulocytes 21,236 nTPM).
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"H3-3B" OR ABSTRACT:"H3-3B" OR TITLE:"H3.3 histone B" OR ABSTRACT:"H3.3 histone B" OR TITLE:"Histone H3.3" OR ABSTRACT:"Histone H3.3" OR TITLE:"H3.3B" OR ABSTRACT:"H3.3B" OR TITLE:"H3F3B" OR ABSTRACT:"H3F3B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about H3-3B, not a curated reading list.
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), CIViC.
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), CIViC, Open Targets Platform.
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), CIViC, Open Targets Platform.
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), Melanoma.
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), Melanoma.